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AsiaObjectives: To describe long-term antithrombotic management patterns (AMPs) in medically managed Asian
patients with non-ST-segment myocardial infarction (NSTEMI) or unstable angina (UA).
Background: Current guidelines support an early invasive strategy in NSTEMI and UA patients, but many are
medically managed, and data are limited on long-term AMPs in Asia.
Methods: Data were analyzed frommedicallymanaged NSTEMI and UA patients included in the prospective, ob-
servational EPICOR Asia study (NCT01361386). Survivors to hospital discharge were enrolled (June 2011 to May
2012) from 8 countries/regions across Asia. Baseline characteristics and AMP use up to 2 years post-discharge
were collected. Outcomes were major adverse cardiovascular events (MACE: myocardial infarction, ischemic
stroke, and death) and bleeding.
Results: Among 2289medically managed patients, dual antiplatelet therapy (DAPT) use at dischargewas greater
in NSTEMI than in UA patients (81.8% vs 65.3%), and was significantly associated with male sex, positive cardiac
markers, and prior cardiovascular medications (p < 0.0001). By 2 years, 57.9% and 42.6% of NSTEMI and UA
patients, respectively, were on DAPT. On multivariable Cox regression analysis, risk of MACE at 2 years was
most significantly associated with older age (HR [95% CI] 1.85 [1.36, 2.50]), diagnosis of NSTEMI vs UA (1.96
[1.47, 2.61]), and chronic renal failure (2.14 [1.34, 3.41]), all p ≤ 0.001. Risk of bleeding was most significantly
associated with region (East Asia vs Southeast/South Asia) and diabetes.
Conclusions: Approximately half of all patients were on DAPT at 2 years. MACE were more frequent in NSTEMI
than UA patients during follow-up.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).attern; DAPT, dual antiplatelet
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Current international guidelines support the use of an early invasive
strategy in the management of male and female adult patients with
non-ST-segment elevation acute coronary syndromes (NSTE-ACS),
comprising non-ST-segment elevation myocardial infarction (NSTEMI)
or unstable angina (UA) [1–5]. Nevertheless, many of these patients
do not undergo revascularization and have poorer long-term outcomes
compared with NSTE-ACS patients managed invasively [6]. Reasons for
non-revascularization are unclear but are possibly associated withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cultural reluctance among some patients [6].
There is no consensus regarding the management of medically man-
agedNSTE-ACSpatients, and there are fewdata relating to antithrombotic
management patterns (AMPs) used and long-term outcomes in these pa-
tients in Asia [6]. This analysis used data fromnon-revascularizedNSTEMI
and UA patients from the EPICOR Asia (Long-tErm Follow-uP of anti-
thrombotIc Management Patterns In Acute CORonary Syndrome Patients
in Asia) study (NCT01361386) [8] who survived to discharge, and were
followed up for up to 2 years post-discharge, to describe AMPs used




Data were analyzed from NSTE-ACS patients treated with medica-
tion only in EPICOR Asia, a prospective, multinational, observational co-
hort study. Patients with ACS who survived to hospital discharge were
enrolled between June 2011 and May 2012 from 8 countries/regions
across Asia. Patient data relating to final diagnosis, baseline
demographics and clinical characteristics, and AMPs used in hospital,
at discharge, and up to 2 years post-discharge, were collected. Post-
discharge data on AMPs and cardiovascular and bleeding events were
collected by means of telephone interviews at 6 weeks and then every
3 months, and events were validated based on real-time reports.
Predefined in-hospital major cardiovascular complications included
myocardial infarction (MI) and ischemic stroke, and post-discharge
major adverse cardiovascular events (MACE) included MI, ischemic
stroke, and death. These were recorded both as composite and individ-
ual endpoints.
Study procedures adhered to International Conference on Harmoni-
zation (ICH)GoodClinical Practice guidance, theDeclaration of Helsinki,
and local regulations. Institutional Review Board/Ethics Committee ap-
proval was obtained at each participating center in each country. All pa-
tients provided written informed consent.
2.2. Objectives
To describe in-hospital, discharge, and long-term AMPs, and ische-
mic and bleeding outcomes in medically managed Asian patients sur-
viving hospitalization for NSTEMI or UA who were followed for up to
2 years post-discharge.
2.3. Statistical analysis
To describe real-world outcomes, an intention-to-treat assessment
of index event, AMPs used, and outcomes was performed, unadjusted
for baseline differences in patient characteristics or treatment selection;
therefore, as this was an observational rather than a randomized study,
a causal association between AMPs and outcomes could not be
established. Low use of antithrombotic therapy was defined as 0–1 an-
tiplatelet +0–1 heparin/anticoagulant and no glycoprotein (GP) IIb/
IIIa inhibitor. Dual antiplatelet therapy (DAPT) was defined as 2 or
more antiplatelet agents. In-hospital cardiovascular complications in-
cluded MI and ischemic stroke but not death, as patients who died in
hospital were excluded from the study. Comparisons of baseline patient
characteristics between single antiplatelet therapy (SAPT) and DAPT
use at discharge were performed. Exploratory analysis of risk factors
for cardiovascular and bleeding events up to 2 years post-discharge
was performed using multivariable Cox regression analysis – with
models containing AMP at discharge (≥2 antiplatelets [no anticoagu-
lant] vs 1 antiplatelet [no anticoagulant], and any anticoagulant vs 1 an-
tiplatelet [no anticoagulant]), diagnosis (NSTEMI, UA), age, gender,
region, hypertension, hypercholesterolemia, diabetes mellitus, family20history of coronary artery disease (CAD), current smoking, obesity
(body mass index >30 kg/m2), prior MI, previous percutaneous coro-
nary intervention (PCI), previous coronary artery bypass graft, coronary
angiogram diagnostic for CAD, chronic angina, heart failure, atrial fibril-
lation, transient ischemic attack/stroke, peripheral vascular disease, and
chronic renal failure – and presented in terms of hazard ratio (HR) and
associated 2-sided 95% confidence intervals (CIs). Covariates were se-
lected based on clinical evaluation of potential prognostic value, in-
formed by other investigations that had taken place on the EPICOR [9]
and EPICOR Asia studies.
3. Results
3.1. Patient characteristics
Of 6306 NSTE-ACS patients included in EPICOR Asia, 2289 (36.3%)
were treated withmedication only, of whom 996 (43.5%) had a diagno-
sis of NSTEMI and 1293 (56.5%)UA.Mean ageswere 63.7 and 63.0 years
in NSTEMI and UA patients, respectively, with 20.0% and 14.2% being
over 75 years of age in each category. Most patients (70.1% and 60.2%,
respectively) were male, 33.5% and 27.5% had diabetes, and 26.6% and
18.7% were current smokers (eTable 1).
3.2. In-hospital AMPs
The AMP used most frequently in-hospital was ≥2 antiplatelets plus
heparin/anticoagulant, and no GP IIb/IIIa inhibitor (53.1% of patients);
this regimen was used more in NSTEMI (63.3%) than in UA (45.2%) pa-
tients (eTable 2). Patients with UAweremore frequentlymanagedwith
≥2 antiplatelets only (no anticoagulant/no GP IIb/IIIa inhibitor) com-
pared with NSTEMI patients (34.4% vs 19.0%). Unadjusted analysis
showed a tendency for higher in-hospital cardiovascular complications
with low antithrombotic therapy use in NSTEMI patients (5.6%) com-
pared with greater use (1.3% for ≥2 antiplatelets plus heparin/anticoag-
ulant but no GP IIb/IIIa inhibitor, and 1.4% for ≥2 antiplatelets only and
no anticoagulant or GP IIb/IIIa inhibitor) (eTable 3). Bleeding rates
were also higher with greater versus lower antithrombotic therapy
use (1.7% vs 0.2%, respectively), andwere slightly higher in NSTEMI ver-
sus UA patients (eTable 3). As stated previously, however, causality can-
not be inferred.
3.3. Discharge and long-term AMPs and outcomes
At discharge, themajority of patients were receiving ≥2 antiplatelets
without an anticoagulant; this was higher in NSTEMI (81.8%) compared
with UA patients (65.3%) (Fig. 1 and eTable 4). Use of any anticoagulant
was low during follow-up (<1% of the overall NSTE-ACS population at
each time point, eTable 4). Among 2192 patients discharged on SAPT
(n = 585) or DAPT (n = 1607), there were notable differences by pa-
tient characteristics, including greater DAPT use associated with
NSTEMI, male sex, positive cardiac markers, initial creatinine >1.2 mg/
dl, and pre- or in-hospital use of cardiovascular medications, including
aspirin, clopidogrel, and anticoagulants (Table 1). There were also sig-
nificant differences across hospital type and country of residence.
The overall proportion of patients receiving DAPT gradually de-
creased from72.6% at discharge to 49.1% at 2 years, whereas the propor-
tion of patients receiving SAPT increased from 26.4% to 41.1%, and those
receiving no antiplatelet rose from 0.1% to 8.9% over the same period
(eTable 4). By the end of the 2-year follow-up, more UA than NSTEMI
patients were on 0–1 antiplatelet (56.6% vs 41.0%), whereas more
NSTEMI (57.9%) than UA patients (42.6%) were on DAPT.
The overall incidence of MACE at 2 years was somewhat higher in
patients discharged on DAPT than on SAPT (15.5% vs 10.9%, Table 2),
but NSTEMI patients (i.e. higher risk patients) were more likely to re-
ceive DAPT than SAPT. Thus, risk of MACE in NSTEMI patients was 18%
on SAPT and 20% on DAPT, with corresponding values in UA patients
Fig. 1. Antithrombotic management patterns (AMPs) in (A) Non-ST-segment elevation
myocardial infarction (NSTEMI), (B) Unstable angina, and (C) All non-ST-segment
elevation acute coronary syndrome (NSTE-ACS) patients up to 2 years post-discharge.
Legend: Number of patients on each AMP type over time, including patients who died
or were lost to follow-up. DAPT, dual antiplatelet therapy; None, no antiplatelet therapy;
SAPT, single antiplatelet therapy.
Table 1
Patient characteristics by antiplatelet therapy at discharge following NSTE-ACS in medi-








NSTEMI 964 164 (17.0) 800 (83.0)
Unstable angina 1228 421 (34.3) 807 (65.7)
Age (yrs), mean (SD) 2192 63.5 (11.4) 63.1 (11.7)
>75 361 95 (26.3) 266 (73.9)
Male sex 1415 332 (23.5) 1083 (76.5)
Positive cardiac markersb 961 163 (17.0) 798 (83.0)
Risk factors for CVD 1643 427 (26.0) 1216 (74.0)
Hypertension 1388 363 (26.2) 1025 (73.8)
Hypercholesterolemia 456 101 (22.1) 355 (77.9)
Diabetes mellitus 658 159 (24.2) 499 (75.8)








Current smoking 484 114 (23.6) 370 (76.4)
Obesity (BMI >30 kg/m2) 138 41 (29.7) 97 (70.3)
Prior CVD 900 238 (26.4) 662 (73.6)
Prior MI 310 74 (23.9) 236 (76.1)
Prior PCI 278 57 (20.5) 221 (79.5)
Prior CABG 66 17 (25.8) 49 (74.2)
CAG diagnostic for CAD 380 90 (23.7) 290 (76.3)
Chronic angina 518 148 (28.6) 370 (71.4)
Heart failure 129 30 (23.3) 99 (76.7)
Atrial fibrillation 60 21 (35.0) 39 (65.0)
TIA/stroke 128 41 (32.0) 87 (68.0)
PVD 33 4 (12.1) 29 (87.9)
Chronic renal failure 80 15 (18.8) 65 (81.2)
Initial creatinine >1.2 mg/dl 399 75 (18.8) 324 (81.2)
Antiplatelet therapyc 2192 585 (26.7) 1607 (73.3)
Aspirin 2066 488 (23.6) 1578 (76.4)
Clopidogrel 1944 397 (20.4) 1547 (79.6)
Other prior cardiovascular
medication
β-blocker 1527 374 (24.5) 1153 (75.5)
ACEi/ARB 1382 327 (23.7) 1055 (76.3)
Statin 2019 522 (25.9) 1497 (74.1)
Anticoagulants 1343 257 (19.1) 1086 (80.9)
Discharge hospital type
Community 176 48 (27.3) 128 (72.7)
Non-university general
(n = 496)
496 87 (17.5) 409 (82.5)
University general (n = 1198) 1198 331 (27.6) 867 (72.4)
Other hospital/clinic (n = 322) 322 119 (37.0) 203 (63.0)
Cath lab facilities
Coronary/ICU (n = 2106) 2106 561 (26.6) 1545 (73.4)
Cath lab (n = 2038) 2038 551 (27.0) 1487 (73.0)
Place of residence
Rural (n = 716) 716 162 (22.6) 554 (77.4)
Metropolitan (n = 1476) 1476 423 (28.7) 1053 (71.3)
Insurance typed
Government (n = 1543) 1543 422 (27.3) 1121 (72.7)
Private (n = 186) 186 39 (21.0) 147 (79.0)
Employer-provided (n = 25) 25 9 (36.0) 16 (64.0)
Other (n = 64) 64 9 (14.1) 55 (85.9)
None (n = 391) 391 111 (28.4) 280 (71.6)
Country of residence
China (n = 1374) 1374 396 (28.8) 978 (71.2)
Hong Kong (n = 37) 37 13 (35.1) 24 (64.9)
India (n = 407) 407 121 (29.7) 286 (70.3)
Malaysia (n = 50) 50 7 (14.0) 43 (86.0)
Singapore (n = 17) 17 2 (11.8) 15 (88.2)
South Korea (n = 50) 50 18 (36.0) 32 (64.0)
Thailand (n = 220) 220 25 (11.4) 195 (88.6)
Vietnam (n = 37) 37 3 (8.1) 34 (91.9)
ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI,
bodymass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CAG,
coronary angiography; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; ICU,
intensive care unit; MI, myocardial infarction; NSTE-ACS, non-ST-segment elevation acute
coronary syndrome; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, per-
cutaneous coronary intervention; PVD, peripheral vascular disease; SAPT, single antiplate-
let therapy; SD, standard deviation; TIA, transient ischemic attack.
Values are n (%), unless otherwise indicated and represent number of subjects discharged
on SAPT or DAPT out of those subjects with the row characteristic of interest.
a ≥2 antiplatelet agents.
b Positive cardiac markers were defined as elevated CK-MB and troponins (at least 1
value >99th percentile of the upper reference limit).
c For patientswith no in-hospital antiplatelet use recorded, any discharge antiplatelet is
assumed to have also been used in hospital.
d Patients may have more than 1 insurance.
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21of 8% and 11%. Causality of treatment effect cannot be inferred for rea-
sons such as potential confounders, as described in the limitations sec-
tion of the discussion. With the same proviso, bleeding event rates
were similar regardless of discharge antiplatelet therapy.
Table 2
2-year outcomes according to discharge antithrombotic management patterna.
NSTEMI UA All patients
SAPT (n = 164) DAPT (n = 800) SAPT (n = 421) DAPT (n = 807) SAPT (n = 585) DAPT (n = 1607)
MACE 30 (18.3) 160 (20.0) 34 (8.1) 89 (11.0) 64 (10.9) 249 (15.5)
Death 24 (14.6) 99 (12.4) 18 (4.3) 49 (6.1) 42 (7.2) 148 (9.2)
Myocardial infarction 10 (6.1) 69 (8.6) 8 (1.9) 28 (3.5) 18 (3.1) 97 (6.0)
Ischemic stroke 1 (0.6) 19 (2.4) 11 (2.6) 18 (2.2) 12 (2.1) 37 (2.3)
Bleeding 3 (1.8) 34 (4.3) 26 (6.2) 64 (7.9) 29 (5.0) 98 (6.1)
Major bleedingb 0 10 (1.3) 2 (0.5) 12 (1.5) 2 (0.3) 22 (1.4)
Bleeding by regionc
Overall 41/996 (4.1) 94/1293 (7.3) 135/2289 (5.9)
East Asia 34/452 (7.5) 93/1072 (8.7) 127/1524 (8.3)
Southeast/South Asia 7/544 (1.3) 1/221 (0.5) 8/765 (1.0)
DAPT, dual antiplatelet therapy; MACE, major adverse cardiovascular event; NSTEMI, non-ST-segment elevation myocardial infarction; SAPT, single antiplatelet therapy; UA, unstable
angina.
Values are n (%).
a Causality of treatment effect cannot be inferred due to treatment allocation bias and baseline confounding; i.e., there aremultiple variables associatedwith SAPT orDAPT beyond those
created by the treatment alone.
b Confirmed events only; bleed severity was not recorded for approximately 5% of bleed events.
c For bleeding events by region, SAPT and DAPT at discharge were combined.
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Risk of MACE up to 2 years post-discharge was associated with a
number of baseline risk factors on multivariate Cox regression analysis,
most significantly older age (HR [95% CI] 1.85 [1.36, 2.50], p < 0.0001),
diagnosis of NSTEMI vs UA (1.96 [1.47, 2.61], p < 0.0001), and chronic
renal failure (2.14 [1.34, 3.41], p=0.001) (Fig. 2). A full list of results in-
cluding non-significant covariates is shown in eTable 5. For bleeding
events, baseline risk factors included residency in East Asia vs South-
east/South Asia (HR [95% CI] 5.58 [2.57, 12.10], p<0.0001) and diabetes
(2.07 [1.36, 3.15], p < 0.001). As the HR for region was very high for
bleeding, an exploratory analysis was undertaken to investigate the
possible effect of region and index event diagnosis as confounding fac-
tors (Table 2). The results confirmed that the two were not evenly dis-
tributed, with some small differences in bleeding between UA and
NSTEMI patients within regions; that is, there was a comparatively
high proportion of UA patients in East Asia, and a very small number
of bleeding events in Southeast/South Asia.Fig. 2. Significant baseline risk factors of major adverse cardiovascular events and bleeding eve
AMP at discharge (≥2 antiplatelets vs 1 antiplatelet [neither with anticoagulant], and any antico
hypertension, hypercholesterolemia, diabetes, family history of coronary artery disease (CAD
previous PCI, previous coronary artery bypass graft, coronary angiogram diagnostic for CAD, c
vascular disease, and chronic renal failure. aNo AC. AC, anticoagulant; AP, antiplatelet; CI,
cardiovascular events; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myoca
UA, unstable angina.
224. Discussion
This analysis of data frommedicallymanagedNSTE-ACS patients en-
rolled in the EPICOR Asia study showed that, despite guideline recom-
mendations [3,4], up to 40% of patients hospitalized with NSTE-ACS
did not undergo coronary revascularization, and were treated only
with medication. This may be due to cultural, financial, and/or educa-
tional reasons, or perhaps an inherent relatively high-risk profile of
medically managed patients, who tend to be older, have a more preva-
lent history of cardiovascular disease and more cardiovascular disease
risk factors and comorbidities, and a greater likelihood of treatment in
a center with limited facilities for invasive management [6,7].
This study demonstrated thatmost patients were treatedwith DAPT
until at least 12 months post-discharge (i.e., in accordance with guide-
line recommendations) [10–12], and around half were still on DAPT at
2 years, including 43% of UA patients, contrary to guidelines at the
time the EPICOR Asia study was conducted [10,13]. At discharge,
NSTEMI patients were more likely to receive DAPT than SAPT, withnts up to 2 years post-discharge (Multivariate Cox Regression). Candidate covariates were:
agulant vs 1 antiplatelet [no anticoagulant]), diagnosis (NSTEMI, UA), age, gender, region,
), current smoking, obesity (body mass index >30 kg/m2), prior myocardial infarction,
hronic angina, heart failure, atrial fibrillation, transient ischemic attack/stroke, peripheral
confidence interval; CRF, chronic renal failure; HR, hazard ratio; MACE, major adverse
rdial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic attack;
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risk associated with each diagnosis. On unadjusted analysis, DAPT use
was also more likely in males, and in patients with positive cardiac
markers, elevated serum creatinine, and pre- or in-hospital use of car-
diovascular medications. The results also showed that broad variability
exists across countries in Asia in terms of discharge antiplatelet man-
agement strategy used for patientswithNSTE-ACS, as also reported pre-
viously [6].
In our study, somewhat more patients discharged on DAPT had
experienced a MACE by 2 years than those discharged on SAPT,
although it should be noted that NSTEMI patients (i.e., those with
higher risk) were more likely to be discharged on DAPT than UA
patients. Based on our data, DAPT patients were more likely to have
positive cardiac markers, hypercholesterolemia, and higher initial
creatinine, and more likely to take other cardiovascular medications,
which may indicate that these patients have more serious cardiac,
renal, and lipid metabolism disorders. As we know, these cardiovas-
cular risk factors have a strong association with higher risk of MACE
[14–16]. Thus, it is likely that the difference in event rates was due to
SAPT patients being at lower cardiovascular risk rather than it being a
treatment effect per se.
European Society of Cardiology guidelines recommend administra-
tion of DAPT with low-dose aspirin and a P2Y12 receptor antagonist,
preferably prasugrel or ticagrelor, for at least 12 months following an
ACS event [4], but the influence of long-term AMPs on outcomes of
medically managed NSTE-ACS patients remains to be elucidated. Inter-
estingly, while overall bleeding rates were relatively low, we observed
more bleeding events in UA than NSTEMI patients, even though UA pa-
tients were more likely than NSTEMI patients to receive SAPT (Table 2).
However, as noted in the results, the numbers of patients with bleeding
events were not evenly distributed by region and index event diagnosis.
When included together in themodel, it was region that appeared to be
important. To our knowledge, this is the first report of bleeding events
in medically managed NSTE-ACS up to 2 years post-discharge. Another
EPICOR study report from Spain showed that 4.1% of NSTE-ACS patients
had experienced at least 1 bleeding event at 2 years, with no significant
difference between patients on DAPT or SAPT, but the authors did
not provide separate bleeding event rates for UA and NSTEMI
patients [17]. Bleeding complications following ACS management con-
tinue to occur in the long term after hospital discharge, and may in-
crease the risk of mortality per se and MACE [18], so should be given
serious consideration. Although the EPICOR Asia study did not collect
data on coagulation function, a study byMathur and colleagues showed
that platelet behavior differs between UA and MI [19]. The authors ob-
served that mean platelet volume was higher in UA than in MI patients
(due to increased platelet size in UA), but platelet count and the per-
centage of platelets expressing P-selectin were lower in UA, indicating
that coagulation states are different in these 2 patient groups.
4.1. Study limitations
In terms of potential limitations, and as stated earlier, this observa-
tional analysis did not allow assessment of comparative effectiveness
of AMPs, and causality of treatment effect on cardiovascular and bleed-
ing events cannot be inferred due to treatment allocation bias and base-
line confounding; that is, there are multiple variables associated with
SAPT or DAPT beyond those created by the treatment alone. Although
the analysis can be clinically interpreted if SAPT and DAPT at discharge
are viewed asmarkers for comorbidity and concurrentmedications, the
findings in relation to outcomes should be interpreted with caution.
Furthermore, the study was carried out largely before the availability
of the more potent antiplatelet agents, prasugrel and ticagrelor.
Although prasugrel was not observed to achieve a significant reduction
in cardiovascular event rates compared with clopidogrel in medically
managed NSTE-ACS patients [20], ticagrelor showed consistent
cardiovascular benefit versus clopidogrel in NSTE-ACS patients23intended for medical management [21,22], and in Asian and non-
Asian ACS patients [23].
5. Conclusions
In conclusion, this analysis of patients from EPICOR Asia provided a
unique opportunity to describe long-term management patterns in
medically managed NSTE-ACS patients across the Asian region.
NSTEMI patients were more likely than UA patients to receive DAPT at
discharge, and approximately half of all patients remained on DAPT by
the end of the 2-year follow-up period.MACE occurredmore frequently
in NSTEMI than in UA patients during long-term follow-up. Although
bleeding events appeared higher in UA patients, region was shown to
be a confounder.
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